Chugai Pharmaceutical Co (TSE:4519) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4519 Chugai Pharmaceutical Co Ltd TSE:4519
97 GF Score
Price 円7,230.00
GF Value 円7,735.19
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co FFO?

FFO (Funds from operations) only applies to REITs.

TSE:4519
97GF Score
Chugai Pharmaceutical Co Ltd TSE:4519
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of 円7,230.00 is trading 6.5% below its estimated GF Value™ of 円7,735.19. GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4519:

  • FFO:
  • GF Value™: 円7,735.19 vs. price of 円7,230.00 (6.5% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score

Get the complete analysis for TSE:4519

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円7,230.00
Price
円7,735.19
GF Value